CUPERTINO, Calif., Feb. 28, 2022 /PRNewswire/ -- DURECT Corporation
(Nasdaq: DRRX) today announced that it will report its fourth
quarter and full year 2021 financial results and host a conference
call after the market close on Monday, March
7, 2022.
Monday, March 7 @
4:30pm Eastern Time / 1:30pm Pacific Time
Toll Free:
877-869-3847
International:
201-689-8261
Conference ID: 13727525
Webcast:
https://themediaframe.com/mediaframe/webcast.html?webcastid=qrEvoVo0
About DURECT Corporation
DURECT is a
biopharmaceutical company committed to transforming the treatment
of acute organ injury and chronic liver diseases by advancing novel
and potentially lifesaving therapies based on its endogenous
epigenetic regulator program. Larsucosterol (also known as
DUR-928), DURECT's lead drug candidate, binds to and inhibits the
activity of DNA methyltransferases (DNMTs), epigenetic enzymes
which are elevated and associated with hypermethylation found in
alcohol-associated hepatitis (AH) patients. Larsucosterol is in
clinical development for the potential treatment of AH, for which
FDA has granted a Fast Track Designation; non-alcoholic
steatohepatitis (NASH) is also being explored. In addition,
POSIMIR® (bupivacaine solution) for infiltration use, a non-opioid
analgesic utilizing the innovative SABER® platform technology, is
FDA-approved and has been exclusively licensed to Innocoll
Pharmaceuticals for development and commercialization in
the United States. Full
prescribing information about POSIMIR, including the Boxed Warning,
can be found at www.posimir.com. For more information
about DURECT, please visit www.durect.com and follow
us on Twitter https://twitter.com/DURECTCorp.
DURECT Forward-Looking Statement. This press
release contains forward-looking statements relating to, among
other things, DURECT's relationship with Innocoll, statements about
the potential for larsucosterol (also known as DUR-928) to treat
patients with AH, NASH, multiple acute organ injury, chronic liver
diseases and other diseases, ongoing clinical trials of
larsucosterol, and the potential benefits of Fast Track
Designation. Any statements contained in this press release that
are not statements of historical fact may be deemed to be
forward-looking statements. Words such as "planned," "will," "may,"
"expect," "anticipate," and similar expressions are intended to
identify these forward-looking statements. These forward-looking
statements are based on DURECT's current expectations and
inherently involve significant risks and uncertainties. Actual
results and the timing of events could differ materially from those
anticipated in such forward looking statements as a result of these
risks and uncertainties, which include, without limitation, risks
and uncertainties that Innocoll may not launch POSIMIR as planned
or commercialize POSIMIR successfully, if at all, the risk that the
clinical trial of larsucosterol in AH takes longer to conduct than
anticipated due to COVID-19 or other factors, the risk that
clinical trials of larsucosterol, including AHFIRM, do not confirm
the results from earlier clinical or pre-clinical trials, or do not
demonstrate the safety or efficacy or the lifesaving potential of
larsucosterol in a statistically significant manner, the risk that
Fast Track Designation for larsucosterol in AH may not lead to
faster FDA review or an approval, risks related to DURECT's ability
to obtain capital to fund operations and expenses, risks related to
market competition, and other risks described in the "Risk Factors"
section of DURECT's Quarterly Report on Form 10-Q for the period
ended September 30, 2021 filed with
the Securities and Exchange Commission (the "SEC") on November 3, 2021, and in other filings filed from
time to time with the SEC. DURECT does not undertake any obligation
to update forward-looking statements and expressly disclaims any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein,
except as required by law.
NOTE: POSIMIR® is a trademark of Innocoll Pharmaceuticals, Ltd.
in the U.S. and a trademark of DURECT Corporation outside of the
U.S. SABER® is a trademark of DURECT Corporation. Other
referenced trademarks belong to their respective
owners. Larsucosterol (DUR-928) is an investigational drug
candidate under development and has not been approved for
commercialization by the U.S. Food and Drug
Administration or other health authorities for any
indication.
View original
content:https://www.prnewswire.com/news-releases/durect-corporation-to-announce-fourth-quarter-and-full-year-2021-financial-results-and-provide-business-update-on-march-7-301492013.html
SOURCE DURECT Corporation